Page last updated: 2024-11-12

dextromethorphan - quinidine combination

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dextromethorphan - quinidine combination: for the treatment of pseudobulbar affect in ALS, the combination of 30 mg DM and 30 mg Q is referred to as AVP-923, Note: Neurodex is a multimeaning Tradename [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9916632
MeSH IDM0493994

Synonyms (10)

Synonym
zenvia
quinidine - dextromethorphan combination
dextromethorphan - quinidine combination
avp-923
neurodex
avp 923
634202-74-7
DTXSID90979599
6'-methoxycinchonan-9-ol--3-methoxy-17-methylmorphinan (1/1)
(s)-[(2r,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;(1s,9s,10s)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Adverse events were mostly mild or moderate and of expected types."( Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study.
Hepner, A; Pope, LE; Shaibani, AI; Thisted, R, 2012
)
0.38
" Safety measures included adverse events (AEs), laboratory tests, electrocardiograms (ECGs), vital signs, and physical examinations."( An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
Appel, SH; Formella, AE; Lomen-Hoerth, C; Pattee, GL; Pope, LE; Wymer, JP, 2014
)
0.4
" Adverse events included headache (7."( An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
Cutler, AJ; D'Amico, S; Davis, CS; Doody, RS; Ledon, F; Shin, P; Siffert, J; Yonan, C, 2016
)
0.43
"DM/Q significantly reduced PBA symptoms in patients with dementia; reported adverse events were consistent with the known safety profile of DM/Q."( An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
Cutler, AJ; D'Amico, S; Davis, CS; Doody, RS; Ledon, F; Shin, P; Siffert, J; Yonan, C, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
"In summary, results from this study suggest that maintenance on dextromethorphan in combination with quinidine has a limited role in the treatment of opioid dependence."( Evaluation of the reinforcing and subjective effects of heroin in combination with dextromethorphan and quinidine.
Comer, SD; Sullivan, MA; Vosburg, SK,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" DM has been under investigation for several years as a neuroprotective agent in stroke, neurosurgery and amyotrophic lateral sclerosis (ALS); however, it is rapidly metabolized by CYP2D6, reducing the drug's bioavailability at neuronal targets."( AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain.
Olney, N; Rosen, H, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" Of particular concern to the FDA were increased QTc intervals reported in patients dosed with a 30-/30-mg dose of DM/Q."( AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain.
Olney, N; Rosen, H, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (13.33)29.6817
2010's26 (86.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.14 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index40.78 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (20.00%)5.53%
Reviews12 (34.29%)6.00%
Case Studies7 (20.00%)4.05%
Observational1 (2.86%)0.25%
Other8 (22.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]